on November 4, 2002
Published online before print November 4, 2002, doi: 10.1161/01.CIR.0000041632.02514.14
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on September 3, 2002
From the Catheterization Laboratories, Ospedale San Raffaele and Emo Centro Cuore Columbus, Milan, Italy (F.L., G.S., C.D.M., M.M., A.C.), and the Department of Cardiovascular Pathology (R.V., A.F., F.D.K.), Armed Forces Institute of Pathology, Washington, DC. * To whom correspondence should be addressed. E-mail: virmani{at}afip.osd.mil.
Background—We recently reported delayed angiographic restenosis in 15 patients who received 7-hexanoyltaxol (QP2)-eluting polymer stents (QuaDS) for the treatment of in-stent restenosis. This study presents the histological findings of atherectomy specimens from a subset of these patients receiving implants. Methods and Results—Between October and December 2001, 5 patients treated with QuaDS-QP2 stents underwent directional coronary atherectomy at 11.2±1.0 months for recurrent in-stent restenosis. Restenotic lesion composition was assessed with special stains, immunohistochemistry with quantitative image analysis, and, in one specimen, transmission electron microscopy. Atherectomy specimens contained fibrin interspersed in a smooth muscle cell-rich neointima with proteoglycan matrix. In 2 of 5 specimens, large aggregates of macrophages and T-lymphocytes were noted. These areas of active inflammation demonstrated a relatively high proliferation index by Ki-67 antibody staining, whereas the proliferation index in smooth muscle cell-rich restenotic areas was low. Conclusion—Restenotic lesions from QuaDS-QP2-eluting stents at 12 months show persistent fibrin deposition with varying degrees of inflammation. These pathological changes, representing delayed healing, are usually observed up to only 3 months in human coronary arteries with stainless steel balloon-expandable stents. The nonreabsorbable polymer alone may have induced chronic inflammation.
Accepted on September 19, 2002
Mechanism of Late In-Stent Restenosis After Implantation of a Paclitaxel Derivate-Eluting Polymer Stent System in Humans
Renu Virmani MD*,
Key words: fibrin • inflammation • stents • restenosis
This article has been cited by other articles:
 |
|
 |
|
  J. Mehilli, R. A. Byrne, A. Wieczorek, R. Iijima, S. Schulz, O. Bruskina, J. Pache, R. Wessely, A. Schomig, A. Kastrati, et al. Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis Eur. Heart J., June 11, 2008; (2008) ehn253v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Aoki, A. Kirtane, M. B. Leon, and G. Dangas Coronary Artery Aneurysms After Drug-Eluting Stent Implantation J. Am. Coll. Cardiol. Intv., February 1, 2008; 1(1): 14 - 21. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Wilson and J. T. Willerson Myocardial Revascularization with Percutaneous Devices Card. Surg. Adult, January 1, 2008; 3(2008): 573 - 598. [Full Text]
|
|
|
|
 |
|
 J. Cosgrave, A. Qasim, A. Latib, T. C. Aranzulla, and A. Colombo Very Late Restenosis after Paclitaxel-Eluting Stent Implantation Ann Intern Med, December 18, 2007; 147(12): 885 - 887. [Full Text] [PDF]
|
|
|
|
 |
|
 H.-J. Cho, T.-Y. Kim, H.-J. Cho, K.-W. Park, S.-Y. Zhang, J.-H. Kim, S.-H. Kim, J.-Y. Hahn, H.-J. Kang, Y.-B. Park, et al. The Effect of Stem Cell Mobilization by Granulocyte-Colony Stimulating Factor on Neointimal Hyperplasia and Endothelial Healing After Vascular Injury With Bare-Metal Versus Paclitaxel-Eluting Stents J. Am. Coll. Cardiol., July 18, 2006; 48(2): 366 - 374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Tsimikas Drug-Eluting Stents and Late Adverse Clinical Outcomes: Lessons Learned, Lessons Awaited J. Am. Coll. Cardiol., May 16, 2006; 47(10): 2112 - 2115. [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Raja Drug-Eluting Stents and the Future of Coronary Artery Bypass Surgery: Facts and Fiction. Ann. Thorac. Surg., March 1, 2006; 81(3): 1162 - 1171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Wessely, A. Schomig, and A. Kastrati Sirolimus and Paclitaxel on Polymer-Based Drug-Eluting Stents: Similar But Different J. Am. Coll. Cardiol., February 21, 2006; 47(4): 708 - 714. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kelbaek, L. Thuesen, S. Helqvist, L. Klovgaard, E. Jorgensen, S. Aljabbari, K. Saunamaki, L. R. Krusell, G. V.H. Jensen, H. E. Botker, et al. The Stenting Coronary Arteries in Non-stress/benestent Disease (SCANDSTENT) Trial J. Am. Coll. Cardiol., January 17, 2006; 47(2): 449 - 455. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Mehilli, A. Kastrati, R. Wessely, A. Dibra, J. Hausleiter, B. Jaschke, J. Dirschinger, A. Schomig, and for the Intracoronary Stenting and Angiographic Re Randomized Trial of a Nonpolymer-Based Rapamycin-Eluting Stent Versus a Polymer-Based Paclitaxel-Eluting Stent for the Reduction of Late Lumen Loss Circulation, January 17, 2006; 113(2): 273 - 279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Hofma, W. J. van der Giessen, B. M. van Dalen, P. A. Lemos, E. P. McFadden, G. Sianos, J. M.R. Ligthart, D. van Essen, P. J. de Feyter, and P. W. Serruys Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation Eur. Heart J., January 2, 2006; 27(2): 166 - 170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Aoki, A. Colombo, D. Dudek, A. P. Banning, J. Drzewiecki, K. Zmudka, F. Schiele, M. E. Russell, J. Koglin, P. W. Serruys, et al. Peristent Remodeling and Neointimal Suppression 2 Years After Polymer-Based, Paclitaxel-Eluting Stent Implantation: Insights From Serial Intravascular Ultrasound Analysis in the TAXUS II Study Circulation, December 20, 2005; 112(25): 3876 - 3883. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kelbaek, L. Thuesen, S. Helqvist, L. Klovgaard, E. Jorgensen, S. Aljabbari, K. Saunamaki, L. R. Krusell, G. V.H. Jensen, H. E. Botker, et al. The Stenting Coronary Arteries in Non-stress/benestent Disease (SCANDSTENT) Trial J. Am. Coll. Cardiol., December 13, 2005; (2005) j.jacc.2005.10.045v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Alvarez Jr and N. K. Kapur Drug Eluting Stent Technology: A Paradigm Shift in the Treatment and Prevention of Restenosis Journal of Pharmacy Practice, December 1, 2005; 18(6): 461 - 478. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Pislaru and R. D. Simari The Translation of Transcription Circ. Res., November 25, 2005; 97(11): 1083 - 1084. [Full Text] [PDF]
|
|
|
|
|
|
J. Aoki, A. C. Abizaid, P. W. Serruys, A. T.L. Ong, E. Boersma, J. E. Sousa, and N. Bruining Evaluation of Four-Year Coronary Artery Response After Sirolimus-Eluting Stent Implantation Using Serial Quantitative Intravascular Ultrasound and Computer-Assisted Grayscale Value Analysis for Plaque Composition in Event-Free Patients J. Am. Coll. Cardiol., November 1, 2005; 46(9): 1670 - 1676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Wessely, A. Kastrati, and A. Schomig Late Restenosis in Patients Receiving a Polymer-Coated Sirolimus-Eluting Stent Ann Intern Med, September 6, 2005; 143(5): 392 - 394. [Full Text] [PDF]
|
|
|
|
|
|
M. Togni, S. Windecker, R. Cocchia, P. Wenaweser, S. Cook, M. Billinger, B. Meier, and O. M. Hess Sirolimus-Eluting Stents Associated With Paradoxic Coronary Vasoconstriction J. Am. Coll. Cardiol., July 19, 2005; 46(2): 231 - 236. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. V. Finn, F. D. Kolodgie, J. Harnek, L.J. Guerrero, E. Acampado, K. Tefera, K. Skorija, D. K. Weber, H. K. Gold, and R. Virmani Differential Response of Delayed Healing and Persistent Inflammation at Sites of Overlapping Sirolimus- or Paclitaxel-Eluting Stents Circulation, July 12, 2005; 112(2): 270 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E Karvouni, S Korovesis, and D G Katritsis Very late thrombosis after implantation of sirolimus eluting stent Heart, June 1, 2005; 91(6): e45 - e45. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R Lowe, I B A Menown, G Nogareda, and I M Penn Coronary stents: in these days of climate change should all stents wear coats? Heart, June 1, 2005; 91(suppl_3): iii20 - iii23. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kondyurin, V. Romanova, V. Begishev, I. Kondyurina, R. Guenzel, and M. F. Maitz Crosslinked Polyurethane Coating on Vascular Stents for Enhanced X-ray Contrast Journal of Bioactive and Compatible Polymers, January 1, 2005; 20(1): 77 - 93. [Abstract] [PDF]
|
|
|
|
|
|
G. J. Murphy, A. J. Bryan, and G. D. Angelini Hybrid Coronary Revascularization in the Era of Drug-Eluting Stents Ann. Thorac. Surg., November 1, 2004; 78(5): 1861 - 1867. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Waksman, A. E. Ajani, A. D. Pichard, R. Torguson, E. Pinnow, D. Canos, L. F. Satler, K. M. Kent, P. Kuchulakanti, C. Pappas, et al. Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: The Oral Rapamune to Inhibit Restenosis (ORBIT) study J. Am. Coll. Cardiol., October 6, 2004; 44(7): 1386 - 1392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Vogt, A. Stein, G. Rettemeier, N. Krott, R. Hoffmann, J. v. Dahl, A.-K. Bosserhoff, W. Michaeli, P. Hanrath, C. Weber, et al. Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent Eur. Heart J., August 1, 2004; 25(15): 1330 - 1340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Curcio, D. Torella, G. Cuda, C. Coppola, M. C. Faniello, F. Achille, V. G. Russo, M. Chiariello, and C. Indolfi Effect of stent coating alone on in vitro vascular smooth muscle cell proliferation and apoptosis Am J Physiol Heart Circ Physiol, March 1, 2004; 286(3): H902 - H908. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V Bhatia, R Bhatia, and M Dhindsa Drug-eluting stents: new era and new concerns Postgrad. Med. J., January 1, 2004; 80(939): 13 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Lemos, P. W. Serruys, and J. E. Sousa Drug-Eluting Stents: Cost Versus Clinical Benefit Circulation, June 24, 2003; 107(24): 3003 - 3007. [Full Text] [PDF]
|
|
|
|
|
|
J. E. Sousa, P. W. Serruys, and M. A. Costa New Frontiers in Cardiology: Drug-Eluting Stents: Part II Circulation, May 13, 2003; 107(18): 2383 - 2389. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Mozes and P. Gloviczki Adjuvant Therapy in Lower Extremity Revascularization: Prevention of Early and Intermediate Failures Perspectives in Vascular Surgery and Endovascular Therapy, January 1, 2002; 15(2): 161 - 180. [Abstract] [PDF]
|
|